The WHO fungal priority pathogens list: a crucial reappraisal to review the prioritisation

The Lancet Microbe, Год журнала: 2024, Номер 5(7), С. 717 - 724

Опубликована: Апрель 9, 2024

In October, 2022, WHO published the first fungal priority pathogen list, which categorised 19 entities into three groups (critical, high, and medium), for prioritisation of research efforts. The final ranking was determined via multiple criteria decision analysis, considering both development needs perceived public health importance. this Personal View, we discuss positioning pathogens, namely, Mucorales, Candida spp, Histoplasma Coccidioides Paracoccidioides Fusarium eumycetoma causative agents, Talaromyces marneffei, Pneumocystis jirovecii, while expressing concerns about potential disparities between list actual disease burden associated with these pathogens. Finally, propose a revised that also considers regional in diseases.

Язык: Английский

---

Global guideline for the diagnosis and management of candidiasis: an initiative of the ECMM in cooperation with ISHAM and ASM

The Lancet Infectious Diseases, Год журнала: 2025, Номер unknown

Опубликована: Фев. 1, 2025

Язык: Английский

---

Addressing Microbial Resistance Worldwide: Challenges over Controlling Life-Threatening Fungal Infections

Pathogens, Год журнала: 2023, Номер 12(2), С. 293 - 293

Опубликована: Фев. 10, 2023

Fungal infections are a serious global concern because of their ability to spread and colonize host tissues in immunocompromised individuals. Such have been frequently reported worldwide currently gaining clinical research relevance owing resistant character, representing bottleneck treating affected people. Resistant fungi an emergent public health threat. The upsurge such pathogens has led new toward unraveling the destructive potential evoked by these species. Some fungi—grouped into Candida, Aspergillus, Cryptococcus—are causative agents severe systemic infections. They associated with high mortality rates recently described as sources coinfection COVID-hospitalized patients. Despite efforts elucidate challenges colonization, dissemination, infection severity, immunopathogenesis fungal diseases remains pivotal characteristic burden elimination. struggle between immune system physiological strategies maintain cellular viability is complex. In this brief review, we highlight drug resistance phenotypes significance, taking consideration physiopathology how scientific community could orchestrate avoid dissemination deaths.

Язык: Английский

---

Microbial lipopeptides: their pharmaceutical and biotechnological potential, applications, and way forward

World Journal of Microbiology and Biotechnology, Год журнала: 2024, Номер 40(4)

Опубликована: Март 15, 2024

Язык: Английский

---

Mortality in chronic pulmonary aspergillosis: a systematic review and individual patient data meta-analysis

The Lancet Infectious Diseases, Год журнала: 2024, Номер unknown

Опубликована: Ноя. 1, 2024

Язык: Английский

---

Allergic Bronchopulmonary Aspergillosis in Patients With Prior Pulmonary Tuberculosis: A Study on the Burden, Clinic‐Radiological Features, Treatment Outcomes and Comparison With Chronic Pulmonary Aspergillosis and Post‐Tubercular Lung Disease Patients

Mycoses, Год журнала: 2025, Номер 68(2)

Опубликована: Фев. 1, 2025

ABSTRACT Background Post‐tuberculosis lung disease (PTLD) is a precursor to Aspergillus ‐related diseases. While Chronic Pulmonary Aspergillosis (CPA) has been extensively studied in the background of tuberculosis, Allergic Bronchopulmonary (ABPA) reported sporadically with limited information on its prevalence, clinical‐radiological features, and treatment outcomes. Objective This study, conducted high TB burden setting, aimed address this knowledge gap by systematically evaluating ABPA PTLD patients. Methods retrospective cohort study screened patients presenting respiratory or constitutional symptoms persisting for more than 3 months. The objective was report clinical‐radiological‐laboratory data, outcomes ABPA‐PTLD compared CPA (CPA‐PTLD) (PTLD only). Results Out total 1012 patients, seen 2.27%, 20.75% sensitization 0.7%. primarily presented breathlessness (91.3%) cough (82.6%) while haemoptysis (43.5%), weight loss (13%), anorexia (21.7%) were also observed, albeit less commonly CPA‐PTLD. Bronchiectasis (100%) nodules (87%) frequent whereas consolidation (21.7%), cavities (30.4%), pleural thickening (8.7%), ‘fungal ball’ (9.1%) seen, although Most received azoles (78%) as first‐line therapy, symptomatic improvement (partial/complete) observed ~78%. Conclusion may occur specific clinical (e.g., haemoptysis) radiological cavity fungal ball) features uncommon other types ABPA, but resembling conditions. Future studies should focus identifying differences natural course appropriate paradigms occurring asthma cystic fibrosis

Язык: Английский

---

A Systematic Review of the Therapeutic Outcome of Mucormycosis

Open Forum Infectious Diseases, Год журнала: 2023, Номер 11(1)

Опубликована: Дек. 30, 2023

Mucormycosis is a potentially lethal mycosis. We reviewed peer-reviewed publications on mucormycosis to assess therapeutic outcomes.

Язык: Английский

---

Poorly controlled asthma – Easy wins and future prospects for addressing fungal allergy

Allergology International, Год журнала: 2023, Номер 72(4), С. 493 - 506

Опубликована: Авг. 4, 2023

Poorly controlled asthma is especially common in low resource countries. Aside from lack of access to, or poor technique with, inhaled beta-2 agonists and corticosteroids, the most problematic forms are frequently associated with both fungal allergy exposure, adults leading to more exacerbations worse asthma. The umbrella term 'fungal asthma' describes many disorders linked exposure and/or fungi. One endotype, ABPA, usually marked by a very high IgE its differential diagnosis reviewed. Both ABPA bronchitis bronchiectasis thick excess airway mucus production. Dermatophyte skin infection can worsen eradication improves Exposure fungi workplace, home schools, often damp water-damaged buildings worsens asthma, remediation symptom control reduces exacerbations. Antifungal therapy beneficial for as demonstrated nine 13 randomised studies, reducing symptoms, corticosteroid need while improving lung function. Other useful therapies include azithromycin some biologics approved treatment severe If all individuals poorly could be 'relieved' their through antifungal without systemic health benefits would enormous relatively inexpensive, long over 20 million children. carries toxicity, drug interactions triazole resistance risks, data incomplete. Here we summarise what known remains uncertain about this complex topic.

Язык: Английский

---

One Health Approach to Addressing Fungal Infection Disparities

Current Fungal Infection Reports, Год журнала: 2024, Номер 18(1), С. 13 - 25

Опубликована: Янв. 16, 2024

Язык: Английский

---

Pan-Indian Clinical Registry of Invasive Fungal Infections Among Patients in the Intensive Care Unit: Protocol for a Multicentric Prospective Study

JMIR Research Protocols, Год журнала: 2024, Номер 13, С. e54672 - e54672

Опубликована: Фев. 16, 2024

Background Fungal infections are now a great public health threat, especially in those with underlying risk factors such as neutropenia, diabetes, high-dose steroid treatment, cancer chemotherapy, prolonged intensive care unit stay, and so on, which can lead to mycoses higher mortality rates. The rates of these have been steadily increasing over the past 2 decades due population patients who immunocompromised. However, data regarding exact burden infection still not available from India. Therefore, this registry was initiated collate systematic on invasive fungal (IFIs) across country. Objective primary aim study is create multicenter digital clinical monitor trends IFIs emerging diseases, well early signals any potential outbreak region. will also capture information antifungal resistance patterns contribution overall morbidity inpatient various conditions. Methods This multicenter, prospective, noninterventional observational be conducted by Indian Council Medical Research through web-based collection method 8 Advanced Mycology Diagnostic Centers Data age, gender, signs symptoms, date admission, discharge or death, diagnostic tests performed, identified pathogen details, susceptibility testing, outcome, obtained hospital records. Descriptive multivariate statistical methods applied investigate manifestations, variables, treatment outcomes. Results These expected find hidden cases setting. facilitate enhancement precision diagnosis prompt modalities response drug sensitivity tests. improve our understanding IFIs, support evidence-based decision-making ability, encourage policies actions. Conclusions diseases neglected problem. Fewer facilities, scanty published data, increased vulnerable patient groups make situation worse. first generated increase related diagnosis, prevention India addressing pertinent gaps mycology. initiative ensure visible impact International Registered Report Identifier (IRRID) DERR1-10.2196/54672

Язык: Английский

---